At a meeting of the Eurasian Economic Commission's Council, the Rules for Conducting Research on Biological Medicinal Products of the Eurasian Economic Union were supplemented with two new chapters.
They regulate the development,
preparation, validation and verification of the quality, efficiency and safety
of high-tech pharmaceuticals based on genetically modified somatic cells. These
include special anti-tumor medicines based on specially treated T-killer cells
that allow treatment of resistant tumor forms.
